PLEURAL MALIGNANT MESOTHELIOMA
Clinical trials for PLEURAL MALIGNANT MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new PLEURAL MALIGNANT MESOTHELIOMA trials appear
Sign up with your email to follow new studies for PLEURAL MALIGNANT MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo targets tough mesothelioma
Disease control OngoingThis study tests whether adding a targeted drug (anetumab ravtansine) to an immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a rare lung cancer called mesothelioma. About 49 adults whose tumors have a specific marker (mesothelin) will take part.…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
Radiation plus immunotherapy shows promise in rare lung cancer trial
Disease control OngoingThis early-stage trial tests whether giving the immunotherapy drug pembrolizumab after radiation therapy is safe and tolerable for people with pleural malignant mesothelioma, a rare cancer of the lung lining. The study involves 24 participants and focuses on side effects, overall…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
Promising drug cocktail targets tough mesothelioma
Disease control OngoingThis study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. About 117 participants who have not had prior treatment will receive either…
Matched conditions: PLEURAL MALIGNANT MESOTHELIOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:07 UTC